PMID- 28076323
OWN - NLM
STAT- MEDLINE
DCOM- 20170821
LR  - 20220409
IS  - 1949-2553 (Electronic)
IS  - 1949-2553 (Linking)
VI  - 8
IP  - 8
DP  - 2017 Feb 21
TI  - Clinical outcome of tyrosine kinase inhibitors alone or combined with 
      radiotherapy for brain metastases from epidermal growth factor receptor (EGFR) 
      mutant non small cell lung cancer (NSCLC).
PG  - 13304-13311
LID - 10.18632/oncotarget.14515 [doi]
AB  - This study compared treatment outcomes between TKI monotherapy and TKI 
      administration combined with brain radiotherapy (TKI + RT) in 133 non-small cell 
      lung cancer (NSCLC) patients with brain metastasis (BM). We also evaluated the 
      association of different epidermal growth factor receptor (EGFR) mutation 
      subtypes with treatment outcome. To screen for potential variables affecting 
      cranial progression free survival (PFS) and overall survival (OS), we performed 
      univariate and multivariate analysis based on Cox proportional-hazards models. 
      Median cranial PFS and OS were longer for the TKI + RT group (n = 67) than TKI 
      alone group (n = 66). Intracranial metastasis correlated with a better median OS 
      than extracranial metastasis. For patients with exon 21 mutations, TKI + RT 
      yielded a better median OS and cranial PFS than TKI alone. However, there were no 
      significant differences in median OS and cranial PFS between the two treatment 
      groups for patients with exon 19 deletions. Thus EGFR-mutant NSCLC patients with 
      BM could benefit more from TKI + RT than from TKI monotherapy, especially when 
      they suffer from exon 21 mutations. However, TKI + RT confers no advantage over 
      TKI treatment alone for patients with exon 19 deletions. These results underscore 
      the urgent need to develop individualized disease management strategies in 
      clinical practice.
FAU - Zhu, Qianqian
AU  - Zhu Q
AD  - Department of Radiation Oncology, The Affiliated Cancer Hospital of Zhengzhou 
      University, Zhengzhou 450000, Henan Province, China.
FAU - Sun, Yanan
AU  - Sun Y
AD  - Department of Radiation Oncology, The Affiliated Cancer Hospital of Zhengzhou 
      University, Zhengzhou 450000, Henan Province, China.
FAU - Cui, Yingying
AU  - Cui Y
AD  - Department of Radiation Oncology, The Affiliated Cancer Hospital of Zhengzhou 
      University, Zhengzhou 450000, Henan Province, China.
FAU - Ye, Ke
AU  - Ye K
AD  - Department of Radiation Oncology, The Affiliated Cancer Hospital of Zhengzhou 
      University, Zhengzhou 450000, Henan Province, China.
FAU - Yang, Chengliang
AU  - Yang C
AD  - Department of Radiation Oncology, The Affiliated Cancer Hospital of Zhengzhou 
      University, Zhengzhou 450000, Henan Province, China.
FAU - Yang, Daoke
AU  - Yang D
AD  - Department of Radiation Oncology, The First Affiliated Hospital of Zhengzhou 
      University, Zhengzhou 450000, Henan Province, China.
FAU - Ma, Jie
AU  - Ma J
AD  - Department of Radiation Oncology, The Affiliated Cancer Hospital of Zhengzhou 
      University, Zhengzhou 450000, Henan Province, China.
FAU - Liu, Xiao
AU  - Liu X
AD  - Department of Radiation Oncology, The Affiliated Cancer Hospital of Zhengzhou 
      University, Zhengzhou 450000, Henan Province, China.
FAU - Yu, Jinming
AU  - Yu J
AD  - Department of Radiation Oncology, Shandong Cancer Hospital Affiliated to Shandong 
      University, Jinan, 250117, Shandong Province, China.
FAU - Ge, Hong
AU  - Ge H
AD  - Department of Radiation Oncology, The Affiliated Cancer Hospital of Zhengzhou 
      University, Zhengzhou 450000, Henan Province, China.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Oncotarget
JT  - Oncotarget
JID - 101532965
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Protein Kinase Inhibitors)
RN  - EC 2.7.10.1 (EGFR protein, human)
RN  - EC 2.7.10.1 (ErbB Receptors)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Antineoplastic Agents/administration & dosage
MH  - Brain Neoplasms/genetics/secondary/*therapy
MH  - Carcinoma, Non-Small-Cell Lung/genetics/secondary/*therapy
MH  - Chemoradiotherapy/*methods
MH  - Cranial Irradiation/methods
MH  - Disease-Free Survival
MH  - ErbB Receptors/*genetics
MH  - Female
MH  - Humans
MH  - Kaplan-Meier Estimate
MH  - Lung Neoplasms/genetics/pathology/*therapy
MH  - Male
MH  - Middle Aged
MH  - Mutation
MH  - Proportional Hazards Models
MH  - Protein Kinase Inhibitors/administration & dosage
MH  - Retrospective Studies
MH  - Treatment Outcome
PMC - PMC5355097
OTO - NOTNLM
OT  - brain metastases
OT  - epidermal growth factor receptor
OT  - non-small cell lung cancer
OT  - radiotherapy
OT  - tyrosine kinase inhibitors
COIS- CONFLICTS OF INTEREST None.
EDAT- 2017/01/12 06:00
MHDA- 2017/08/22 06:00
PMCR- 2017/02/21
CRDT- 2017/01/12 06:00
PHST- 2016/08/31 00:00 [received]
PHST- 2016/12/27 00:00 [accepted]
PHST- 2017/01/12 06:00 [pubmed]
PHST- 2017/08/22 06:00 [medline]
PHST- 2017/01/12 06:00 [entrez]
PHST- 2017/02/21 00:00 [pmc-release]
AID - 14515 [pii]
AID - 10.18632/oncotarget.14515 [doi]
PST - ppublish
SO  - Oncotarget. 2017 Feb 21;8(8):13304-13311. doi: 10.18632/oncotarget.14515.